

Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways

Laurence Michel, P. Reygagne, P. Benech, F. Jean-Iouis, S. Scalvino, S. Ly Ka So, Z. Hamidou, S. Bianovici, J. Pouch, B. Ducos, et al.

▶ To cite this version:

Laurence Michel, P. Reygagne, P. Benech, F. Jean-louis, S. Scalvino, et al.. Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways. British Journal of Dermatology, 2017, 177 (5), pp.1322-1336. 10.1111/bjd.15577 . hal-03502150

HAL Id: hal-03502150 https://hal.science/hal-03502150

Submitted on 24 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signaling pathways

L. Michel^{1,2§†}, P. Reygagne^{3†}, P. Benech^{4,5†}, F. Jean-Louis^{1,2}, S. Scalvino⁶, S. Ly Ka So¹, Z. Hamidou³, S. Bianovici³, J. Pouch⁷, B. Ducos^{7,8}, M. Bonnet¹, A.Bensussan^{1,2}, A. Patatian⁵, E. Lati^{5,6}, J. Wdzieczak-Bakala⁹, J-C. Choulot¹⁰, E. Loing¹¹, M. Hocquaux¹¹.

¹ Inserm UMR976, Skin Research Institute, F-75475 Paris, France

² Univ. Paris Diderot, Sorbonne Paris-Cité, Hôpital Saint-Louis, F-75475 Paris, France

³ Centre Sabouraud, F-75475 Paris, France

⁴ NICN UMR 7259 CNRS Faculté de médecine 13344 Marseille, France

⁵ GENEX, 91160 Longjumeau, France

⁶Laboratoire BIO-EC, 91160 Longjumeau, France

⁷ Plateforme de qPCR à Haut Débit Genomic Paris Centre, IBENS, 75005 Paris, France

⁸ Laboratoire de Physique Statistique, École Normale Supérieure, PSL Research University,

Univ. Paris Diderot, Sorbonne Paris-Cité, CNRS, 75005 Paris, France

⁹ ICSN, 91198 Gif-sur-Yvette, France

¹⁰ Ales groupe, 95871 Bezons, France

¹¹ IEB-Lucas Meyer Cosmetics, 31520 Ramonville, France

This work was conducted in Paris, France.

[§] Corresponding Authors:

Laurence MICHEL

INSERM U976, Pavillon Bazin, Hôpital Saint-Louis. 1, avenue Claude Vellefaux. 75010

Paris, France

Tel: +33 (0)1 53 72 20 55. Fax: +33 (0)1 53 72 20 51

Email address: laurence.michel@inserm.fr;

Michel et al.

Pascal REYGAGNE : p.reygagne@libertysurf.fr

[†] These authors contribute equally to the work

Word count: 3867

Figure count: 5 Table count: 3

Short title (45 characters): Gene regulation in male androgenetic alopecia

Key words: male androgenetic alopecia, gene expression, signaling pathways, development, inflammation.

Abbreviations

ACTH : Adrenocorticotropic hormone AGA : androgenetic alopecia AGRP : agouti-related peptide α -MSH : α -melanocyte stimulating hormone AR : androgen receptor ASIP : agouti signaling protein BAMBI : BMP and activin membrane-bound inhibitor BMP : Bone morphogenetic protein CTNNB1 : β-catenin1 CTSG : cathespin G CMA1 : chymase CYP27B1 : Cytochrome p450 family 27 subfamily B, polypeptide 1 DGA : discriminatory genes analyses DHT : 5-alpha dihydrotestosterone DKK1 : dickkopf Wnt signaling pathway inhibitor 1 DLX3 : Distal-less homeobox 3 DP : dermal papilla DSG4 : desmoglein 4 HF: hair follicles ID3 : Inhibitor of DNA binding 3 ITGB6 : Integrin Beta 6 LEF1 : lymphoid enhancer binding factor 1 LGR5 : Leucin-Rich repeat containing G protein-coupled receptor 5 MC : mast cells POMC : proopiomelanocortin PTGDS : prostaglandin D₂ synthase S100A7 : psoriasin SC : stem cells SFRP2 : secreted Frizzled-related protein 2 TH : tyrosine hydroxylase TPSAB / TPSAD : tryptase alpha / tryptase delta VGF : Nerve Growth factor inducible VDR : vitamin D receptor

ABSTRACT

Background: Male androgenetic alopecia (AGA) is the most common form of hair loss in men and is characterized by a distinct pattern of progressive hair loss starting from the frontal area and the vertex of the scalp. Although several genetic risk loci have been identified, relevant genes for AGA remain to be defined.

Objectives: Herein, molecular biomarkers associated with premature AGA were identified through gene expression analysis using cDNA generated from scalp vertex biopsies of hairless/bald men with premature AGA and healthy volunteers.

Results: This monocentric study reveals that genes encoding mast cell granule enzymes, inflammatory and immunoglobulin-associated immune mediators were significantly overexpressed in AGA. In contrast, under-expressed genes appear to be associated with the Wnt/ β -catenin and BMP/TGF- β signaling pathways. Although involvement of these pathways in hair follicle regeneration is well-described, functional interpretation of the transcriptomic data highlights different events that account for their inhibition. In particular, one of these events depends on the dysregulated expression of proopiomelanocortin (POMC), as confirmed by RT-qPCR and immunohistochemistry. In addition, lower expression of CYP27B1 in AGA subjects supports the notion that changes in vitamin D metabolism contributes to hair loss.

Conclusion: This study provides compelling evidence for distinct molecular events contributing to alopecia that may pave way for new therapeutic approaches.

INTRODUCTION

Male pattern baldness or male androgenetic alopecia (AGA) is the most common type of baldness, characterized by progressive patterned hair loss from the scalp, starting in the frontal area and the vertex, following a defined pattern^{1,2}. It is caused by a shortening of the anagen phase of hair cycling and progressive miniaturization of the hair follicle (HF), which results in the formation of vellus hairs that eventually atrophy³. Up to 80% of European men are concerned by AGA during their life. Although the precise etiology and pathogenesis of androgenetic alopecia are still unclear, genetic and androgenic factors play definite roles. Androgens, especially the metabolite 5-alpha dihydrotestosterone (DHT), affect genetically susceptible cells of the dermal papilla (DP), specialized mesenchymal derived part of the HF, causing progressive HF miniaturization and hair cycle abnormalities leading to male AGA⁴.

Polymorphism of the androgen receptor (AR) gene was first identified in association with AGA ^{5,6}. The paradoxical role of androgens in hair follicle biology remains poorly understood: indeed, androgens trigger hair development at puberty and inversely favor AGA in later life. Kretzchmar *et al.*⁷ explored the inhibitory role of androgens by defining a reciprocal relationship between activated Wnt/ β -catenin and AR signaling within the HF. They pinpointed AR as a negative regulator of β -catenin signaling. However, identification of various new susceptibility genes, such as those on chromosomes 3q26 and 20p11^{8,9}, suggests that non-androgen-dependent pathways are also involved, as reviewed by Heilmann-Heimbach et al¹⁰

HF contains a well-described stem cell niche in the bulge area of the hair, close to the sebaceous glands. After the anagen phase, the catagen phase is followed by migration of stem cells (SC) from the bulge to the bulb to regenerate a new hair. In alopecia, the anagen phase becomes shorter and the number of follicles in the anagen phase decreases. It has been suggested that stem cell pool remain unaffected in AGA patient whereas progenitor cells

arising from stem cells are much more numerous in the follicles of AGA subjects compared to controls¹¹.

Although genetic predisposition and the role of genes in AGA have been documented in several previous reports ^{12,13}, inheritance of male AGA is not fully understood. Also, the full mechanism of hair growth impairment in this disorder remains to be elucidated. The aim of this study is to focus on biomarkers associated with AGA through transcriptomic analyses of scalp biopsies from AGA subjects

MATERIAL AND METHODS

Selection of individuals with AGA and controls

This monocentric study was approved by at the Ethics Committee of Saint-Louis Hospital and the study described adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants. Individuals with any systemic diseases were excluded from the study, and 28 male young Caucasian volunteers were selected for the study and allocated into the two following groups: - group A: Fourteen hairless/bald participants (alopecia, "A"; age: 29.4 ± 3.4), with premature AGA, with stage V to VII according to the Hamilton's classification as modified by Norwood; - group C: Fourteen control subjects (controls, "C"; age: 26.1 ± 3.6) with <2% white hairs and stage I or II in the Hamilton's classification as modified by Norwood.

Gene analysis from cutaneous biopsies.

Two scalp biopsies (2 mm diameter each) were carried out on the vertex, either at the edges of alopecia area in the group A subjects, or at a similar emplacement for the the control group. Biopsies were immediately frozen and kept for further RNA extraction or immunostaining. RNA was isolated using a standard RNA extraction protocol (Trizol[®] Reagent, Ambion by

Life Technologies, Courtaboeuf, France). Extracted RNA samples were quality checked using the Agilent 2100 Bioanalyzer platform (Agilent Technologies, Les Ulis, France).

Gene expression analysis of human skin biopsies was performed using Agilent Whole Human Genome Oligo Microarrays (*onecolor*, 8x60K, v2). Bioinformatical analysis of the microarray experiments was obtained from the single-color hybridization of human cDNA samples to Agilent microarrays and was structured in four main parts: - data preprocessing that covers all necessary data transformations as well as an assessment of variability between the samples, and the detection of potential outliers by a global correlation analysis; - discriminatory genes analyses (DGAs) of pairwise comparisons between A *vs* C groups in order to characterize the differences between the various sample groups based on their gene expression profiles; functional annotation analysis (FAA);- annotation enrichment analysis (AEA) of differentially expressed genes in order to provide an overview of the different biological processes and pathways which are regulated in the discriminatory analyses.

Secondary analysis of the main metabolic pathways and their potential dysfunctions was performed using the Java/Perlsoftware Predictsearch[®] (PS-V5) ¹⁴. The gene expression value cutoff was 60 for all the analyses. This text-mining-based software was used to search and retrieve correlations between modulated genes and biological processes to characterize pathways and functional networks.

Real-Time Quantitative PCR Analysis

Validation of some potent genes depicted by DGA, FAA, and PredictSearch analysis of the identified genes using microarrays was subsequently assessed by analysis of 45 genes by Real Time quantitative PCR (RT-qPCR)¹⁵ using aliquots of the RNA prepared for the microarrays (details in Supplementary Materials and Methods). Furthermore, to improve our study, the isolated total RNA were also subjected to reverse transcription (FluidigmTM,

Les Ulis, France) prior to high throughput RT-qPCR analysis using the same primers ^{16, 17} (Biomark-HD system, Fluidigm[™]) (Supplementary Materials and Methods).

Histochemical analysis.

The frozen biopsies from the vertex were cut in 7µm sections using a Leica CM 3050 cryostat. Sections were then mounted on Superfrost[®] plus silanized glass slides. The sections were blocked for 30 min in 10% goat serum and incubated with anti-POMC (Abcam, ab32893, Paris, France) and anti-ASIP/PARD3 (Abcam, ab64646) before visualized with AlexaFluor 488 (Invitrogen, A11078), and propidium iodide (Sigma, L'Isle d'Abeau, France) for nuclear staining. The microscopic observations were realized using a Leica DMLB or Olympus BX43 microscope (Rungis, France). Pictures were digitized with a numeric DP72 Olympus camera with CellD storing software

Statistical analysis.

One-way analysis of variance (ANOVA) was performed followed by Tukey's honest significant difference (HSD) to perform pairwise comparisons. Statistical significance was assessed using the two-sided Student's t test and the Mann-Whitney statistical test for Fluidigm high throughput qPCR analysis and PredictSearch[®] analysis. Presented p values are not corrected for multiple testing. Differences were considered significant at p<0.05 and tendency to significance for 0.05 .

RESULTS AND DISCUSSION

Patient cohorts and Gene expression analysis.

Fourteen young volunteers with male AGA (alopecia group: A) with appearance of hair loss since 1 to 18 years ago (median, 4.7 years) and 14 young control volunteers (control

group: C) were enrolled. Scalp involvement ranged from 10% to 30% (median, 14%) in AGA volunteers. Subjects did not present any other skin involvement or auto-immune disorders. Biopsies were carried out on the scalp as indicated in figure 1.

A single-color hybridization of human cDNA samples to Agilent Whole Human Genome Oligo Microarrays was assessed with RNA extracted from the scalp biopsies derived from the healthy donors or from the AGA subjects. All probes significantly modulated between A and C samples (Fold Change ≥ 1.5 with a p < 0.05) were included in a cluster analysis, with hierarchically clustered heat maps (Euclidean distance, complete linkage) of reporters (whole cluster analysis available under request). Genes differentially expressed in the group A relative to the group C (GEO deposit GSE90594) were detected using a bioinformatical analysis of the 28 microarrays (http://193.48.40.18/Diffusions IUH/L.MICHEL). Briefly, identification the of differentially expressed genes was done by ANOVA and Tukey post-hoc tests, effect size and detectability. This returned 325 genes upregulated in the alopecia samples relative to the healthy controls and 390 genes with the opposite expression trend (Table 1). After Benjamini-Hochberg correction for multiple testing, the analysis evidenced in fine a final number of 184 significantly down-regulated and 149 up-regulated candidate gene sequences in "A" comparing to "C", respectively (Table 1, Fig.2). Hierarchically clustered heat map representation is shown in Fig.3. An overview of the different biological processes and pathways significantly enriched among the differentially expressed genes was provided by the functional annotation analysis (Table 2, Fig.S1a and S1b). Based on their fold change, a battery of genes was selected and analyzed for mRNA transcript abundancy by high throughput RT-qPCR, confirming for most of them altered gene expression levels in AGA cohort detected by transcriptomic analysis (Fig.4). The DGA gene set was submitted to PredictSearch[®] analysis for functional interpretation and major over- or under-expressed genes were highlighted and associated by gene families (Tables 3A-D). As detailed thereafter, the present transcriptomic data shows an intense activation of immune and inflammatory responses in AGA cohort whereas an inhibition of the Wnt/ β -catenin signaling pathway, of the TGF- β and BMP signaling pathways as well as an alteration of the vitamin D biosynthesis were detected in the AGA subjects.

Activation of immune and inflammatory responses in AGA subjects.

Our data show strong up-regulation of immune and inflammatory genes, as related to B and T lymphocyte recruitment and activation of mast cell (MC), as well as some inflammatory factors related to extracellular matrix as depicted in Fig.4 and Table 3A. Indeed, a significant increase of several chemokines, including CCL13, CCL18, CXCL10 and CXCL12, was detected in our AGA subjects (Fig.3, Table 3A, p<0.01, 0.05, 0.05 and 0.001, respectively). These chemokines play an important role in accumulation of leukocytes during inflammation through potent chemotactic activity, such as CCL13 for recruitment of monocytes, lymphocytes, basophils and eosinophils. Binding of CXCL10 to CXCR3 or CXCL12 to CXCR4 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, as well as modulation of adhesion molecule expression. Increased production of CXCL10 from HF has been shown to induce preferential infiltrates of highly chemoattracted Th1 and Tc1 cells during the acute phase of alopecia areata (AA)^{18,19}. In AGA subjects, its production, as well as that of CCL8, CCL13, CCL26, and IL-8 (which tended to be increased by RT-PCR), should favor inflammation maintenance. Regarding immune response, we also noticed significant upregulation of TNFRSF17 in AGA volunteers (p < 0.05)Also known as B cell maturation antigen (BCMA), and member of the TNF-receptor superfamily ²⁰, this receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell

development and autoimmune responses. Also, CD38, a multifunctional ectoenzyme widely expressed in leukocytes including B and T lymphocytes, is up-regulated in AGA cohort (p<0.02). It has been shown that CD38 might function in cell adhesion, signal transduction and calcium signalling ²¹.

We observed an over-expression of HLA-DPB1 as well as HLA-DQA1, HLA-DRB3 and HLA-DRB4 in AGA volunteers (Fig.4, Table 3A, p<0.005, 0.01, 0.001 and 0.002, respectively). This is in line with previous reports showing that keratinocytes in the bulb of HF from subjects with AA express class II HLA antigens²². This suggests that the mononuclear cell activation in AGA might be linked to the expression of class II HLA antigens on HF keratinocytes, thus triggering a putative autoimmune response. The DGA analysis also revealed an up-regulation of genes encoding for B lymphocyte-produced immunoglobulins, including IGHG1, IGHM and IGJ, in some AGA volunteers. Possibly, lymphocytes attack the lower part of the anagen follicle, with ectopic expression of MHC class I and II molecules on the epithelium of affected HF, suggesting that B, T cells and cytokines play an important role in AGA as depicted in AA where chemokines are regarded as key players that mediate autoimmune inflammation ¹⁹. Furthermore, we detected a slight up-regulation of the gene encoding high-affinity IgE-receptor FccRI/MAS4A2 (membrane-spanning 4-domains, subfamily A, member 2) in AGA subjects (p < 0.001), a receptor found on the surface of MCs and basophils and involved in FccRIdependent signaling. The relationship between mast cells and male pattern hair loss was supported by previous histological evidences showing that perifollicular fibrosis is associated with increase in MC numbers ²³. Similarly, we noticed up-regulated expression of several genes including COLIA1 (p<0.01) or COLIA2 (p<0.01) and genes of several metalloproteinases (MMPs), especially MMP12 (p<0.02), as observed during inflammatory wound-healing ²⁴ (Fig.4, Table 3A). Of interest, our data bring evidence of an activation of MCs in AGA subjects as illustrated by the significant over-expression of MC markers, including *prostaglandin* D_2 *synthase* (*PTGDS*) (*p*<0.01), *KIT/c-kit*, *tryptases* (*TPSAB* (*p*<0.001) and *TPSAD* (*p*<0.001)), *chymase* (*CMA1*) (*p*<0.005) and *cathespin G* (*CTSG*) (*p*<0.0005) (Fig.4, Table 3A). Expression of KIT/c-kit has been shown to be positively controlled by GATA2 in a hair-cycle-dependent manner ²⁵ and its significant up-regulation in the AGA subjects (*p*<0.002) reinforces a functional role of MC and epithelial KIT/c-kit expression in hair growth control. We may suggest that PGD₂ synthesized from prostaglandin H₂ by PTGDS, and previously found highly expressed in AGA ²⁶, could inhibit HF regeneration through binding to the Gpr44 receptor ²⁷. Altogether, our results reinforce the MC involvement in AGA.

Inhibition of the Wnt signaling in AGA patients.

Among genes eliciting a differential expression pattern in AGA subjects and healthy volunteers, a significant number of genes was related to the Wnt/ β -catenin signaling pathway as described in Fig.4 and Table 3B. This pathway plays an important and well-known role in HF development, hair stem cell maintenance, and HF lineage commitment ²⁸ and is required for the induction of hair keratin genes in HF stem cells co-cultured with DP cells ²⁹. Moreover, several studies have reported the inhibition of this pathway in AGA ^{7, 30, 31}.

SFRP2 (secreted Frizzled-related protein 2) and DKK1 (dickkopf Wnt signaling pathway inhibitor 1) are the main known inhibitors of the Wnt signaling ^{32,33}. DKK1-promoting HF regression was shown to be up-regulated in follicular keratinocytes of the late anagen in depilation-induced hair cycle progression ³⁴. While DKK1 expression remained unchanged in our study, expression of *SFRP2* was significantly increased in more than 80% of our AGA subjects (p<0.002). SFRP2, expressed in the epithelial portion of HF, has been shown to be

involved in hair fiber differentiation 35 and as well as in the catagen phase by inhibiting keratinocyte differentiation 36 .

In accordance with this report, we found that expression of *SFRP2* and Wnt target genes such as *LGR5* (p<0.001), *ID3* (p<0.05), MSX2 (p<0.1), *ALAD* (p<0.05), and *BAMBI* (*BMP and activin membrane-bound inhibitor*) (p<0.05) exhibited an inverse relationship (Fig.3, Table 3B). *LGR5* (*Leucin-Rich repeat containing G protein-coupled receptor 5*) is a major Wnt target gene in hair cell progenitors ^{37,38}, and *ID3* (*Inhibitor of DNA binding 3*) encodes a marker in dermal papilla at the middle anagen and telogen stages ³⁹. Noteworthy, *BAMBI* ⁴⁰ encodes the bone morphogenic protein and activin membrane-bound inhibitor, which is known to enhance the Wnt/ β -catenin signalling in various cell types ⁴¹.

In line with reduced expression of these Wnt/ β -catenin target genes, expression of *LEF1* (*lymphoid enhancer binding factor 1*) and *CTNNB1* (β -catenin1), although to a lesser extent, is decreased in the AGA patients (Fig.3, Table 3B, p<0.1 and 0.01, respectively). The products of these genes are known to interact and, after nuclear translocation, to bind to promoter regions of Wnt target genes ^{42,43}. LEF1 is considered as the key transducer of the Wnt signaling pathway, and a potent regulator of hair development ⁴⁴ while CTNNB1 is the major downstream effector of this pathway ^{45,46}.

Noteworthy, our data suggest that alteration of hair regeneration might result also from a dysregulation of *proopiomelanocortin (POMC)* expression, which was reduced in 70% of the AGA cohort compared to controls (Fig.4, Table 3B, *p*<0.001). POMC is the precursor of two hormones: Adrenocorticotropic hormone (ACTH) known as an activator of hair growth ⁴⁷, and α -melanocyte stimulating hormone (α -MSH), which triggers eumelanin synthesis and can protect CTNNB1 from degradation by ubiquitinylation through its inhibitory effect on GSK3 β ⁴⁸.

Moreover, our data showed that one of the highly repressed gene expression in the AGA subjects affected *VGF* (p<0.02), an inducible member of the *Nerve Growth Factor* family that might also contribute to POMC downregulation. Indeed, invalidation of this gene has been shown to lead to a strong alteration of *POMC* expression as well as of neuropeptide Y and AGRP (agouti-related peptide), an antagonist of the α -MSH receptor ⁴⁹.

On the other hand, *ASIP* (*agouti signaling protein*), encoding another antagonist of the α -MSH receptor, was found highly expressed in 86% of the AGA subjects (Fig.4, Table 3B, p<0.005). Thus, it can be suggested that a low level of α -MSH together with high levels of ASIP contributes to impaired CTNNB1 stabilization. Of note, our data in AGA did not only evidence the up-regulation of ASIP but also that of its negative regulator *CORIN*, which encodes a transmembrane serine protease expressed specifically in the DP (Fig.4, Table 3B, p<0.001). However, it was reported in mice that β -catenin activity in the DP suppresses *ASIP* expression and activates *CORIN* while regulating melanocyte activity by a mechanism independent of both ASIP and CORIN⁵⁰. The opposite regulation of ASIP and CORIN by β -catenin in mice is not in line with their co-expression seen nearly in all AGA subjects and such a discrepancy might illustrate distinct regulations among species. Alternatively, activities of the respective gene products may not follow gene expression.

Besides RT-qPCR analysis of *LEF1*, *POMC*, *ASIP* and *CORIN* gene expression to strengthen bioinformatics analysis of transcriptomic data (Fig.4), a histochemical analysis was performed to evaluate whether some of the gene modulations could be detected at protein levels. While both POMC and ASIP expression levels were strongly impaired in AGA patients as shown in figure 5, with scorage intensity in Table 4, POMC was barely detectable in AGA subjects, in line with the results from the transcriptomic data. In contrast, ASIP was more expressed in all HF areas of controls (Fig.5 and Table 4). Thus, a decrease of POMC at both mRNA and protein levels should have a more drastic effect on β -catenin stabilization AGA subjects as compared to controls.

than the increased expression of ASIP. Noteworthy, a lower size of the bulb was observed in

Furthermore, we found that *SRD5A2* encoding the Steroid 5 α -reductase was up-regulated in AGA (Table 3B, p<0.01). This enzyme, known to suppress hair growth activity and to be highly active in balding HF ⁵¹, is involved in the conversion of testosterone into DHT. Interestingly, DHT was reported to activate the interaction between β -catenin and AR ⁵². Such an interaction leads to suppress the β -catenin transcriptional activity, in line with the inhibition of Wnt signaling pathway by androgens in DP cells ³⁰.

TGF-β and BMP signaling pathways in AGA patients.

TGF- β stimulates hair follicle regeneration through Wnt signaling activation and this is achieved via the inhibitory effect of TGF- β on DKK1 ^{53,54}. Among the different members of the TGF- β family, only the expression of *TGFB2* was found negatively modulated in our AGA patients (Fig.4, Table 3C, *p*<0.0001). Several reports have evidenced the role of TGF- β 2 in hair physiology and in particular in HF morphogenesis ⁵⁵.

TGF- β can be activated through its interaction with Integrin Beta 6 (ITGB6) whose gene, known to be up-regulated in the outer root sheath during early hair regeneration ⁵⁴, was under-expressed in AGA (Fig.4, Table 3C, *p*<0.001). Thus, the reduced expression of ITGB6 in AGA is in line with an inhibition of the TGF- β_2 signaling, which impacts negatively folliculogenesis and maturation ⁵⁶. Moreover, expression of other related ITGB6 or TGF- β_2 genes were found underexpressed. Indeed, as ITGB6, its complex associate, *psoriasin* (*S100A7*) ⁵⁷, exhibited a decreased expression in our AGA patients together with several other S100A proteins (Fig.4, *p*<0.05). The expression of these S100A proteins closely coincides with epithelial Ca⁺⁺-regulation, which governs cornified envelope formation in hair follicles

As previously reported in cultured DP cells from AGA ⁵⁹, an underexpression of bone morphogenetic protein 2 (*BMP2*) was observed in our subjects (Table 3C, p<0.02). Together with TGF- β , this reduced expression might decrease the activation of SMAD4 and its target *Distal-less homeobox 3* (*DLX3*) ⁶⁰ as well as it may explain the under-expression of *desmoglein 4* (*DSG4*) we observed in AGA patients (Fig.4, Table 3C, p<0.05 and p<0.02, respectively). Indeed, ablation of SMAD4 was reported to inhibit the expression of *DSG4*, involved in hair follicle integrity and hair shaft differentiation ⁶¹. Of interest, Wnt-, BMP- and TGF- β signaling pathways are all potent transcriptional inducers of BAMBI ⁴⁰. Conversely, inhibition of BAMBI expression as well as that of DLX3 and KRT16 may be triggered by Mir-31, shown to be markedly increased during the anagen and decreased during the telogen and catagen phases ⁶². Accordingly, *KRT16* was also decreased in our AGA patients (Table 3C, p<0.001).

Interestingly, DLX3 ablation has been reported to lead to alopecia through a loss of BMP signaling while DLX3 activates hair formation and differentiation, towards its ability to induce the expression of *GATA3* and *homeobox C13* (*HOXC13*) ⁶³. HOXC13, whose expression was reduced also in our AGA patients (Table 3C, p<0.01), plays a role in the expression of keratin genes ⁶⁴ and in hair follicle differentiation ⁶⁵. In addition to *KRT16*, some AGA patients exhibited an underexpression of a subset of genes encoding keratins (*KRT19, KRT26, KRT39, KRT72, KRT81*) and keratin-associated proteins (KRTAPs) that play a crucial role in hair shaft formation ^{66,67}. We also observed a down-regulation of mesenchymal stem cell markers (Fig.4) such as *SOX9* (p<0.01) and of *Hedgehog-interacting protein* (HHIP) (p<0.02), which is a potent morphogen acting in a wide range

of developmental processes, involved in the Hedgehog signaling and the epithelial-tomesenchymal transition ⁶⁸.

Vitamin D3 signaling in AGA patients.

It has been shown that CTNNB1 and LEF1 can interact with vitamin D receptor (VDR) to form a complex ⁶⁹, and *VDR* gene was found differentially expressed between AGA and controls (Fig.4, p<0.05). Interestingly, VDR–null mice elicit an alopecia phenotype due to a defect in epithelial mesenchymal communication that is required for normal hair cycling ⁷⁰. However, this activity was shown to be independent of the binding of its ligand ⁷¹. On the other hand, calcitriol, the active form of vitamin D3, through binding to VDR, was reported to be responsible for the suppressed expression of DKK1 and SFRP2 in murine bone marrow stromal cells ⁷².

The notion that AGA exhibit an alteration of the vitamin biosynthesis was supported by the decreased expression of *CYP27B1* (Cytochrome p450 family 27 subfamily B, polypeptide 1), in 86% of the AGA subjects (Table 3D, p<0.02). Indeed, expression of CYP27B1 is involved in the synthesis of calcitriol, which elicits a protective role in radiation-induced alopecia ⁷³. Such reduced expression of *CYP27B1* in AGA can be related to the underexpression of *tyrosine hydroxylase* (*TH*) we observed (Table 3D, p<0.05). Known as a transcriptional target of vitamin D3 ⁷⁴, TH is involved in the first step of L-dopa synthesis that activates tyrosinase leading to melanogenesis ⁷⁵. Thus, in addition to the role of POMC and ASIP in hair differentiation and melanogenesis towards their respective impacts on CTNNB1, a decrease of *TH* might explain the progressive replacement of terminal hairs by smaller hairs with less pigmentation observed in AGA.

CONCLUSION

Although RNAs were extracted from whole follicle and not specific follicular compartments, the resulting expression data might reflect the combined amount of distinct RNA populations extracted from different cell types. However, integrating genes within functional networks indicate that the different events observed in our study recapitulate what is known in AGA and therefore ensures consistencies of our results. The present transcriptomic analysis allows us to highlight several specific molecular pathways discriminating AGA individuals from controls as schematized in Fig.6 and to add two new genes POMC and VGF as markers of AGA. It is presently unclear how these events are related to inflammation, mast cell activation, leukocyte recruitment and dysregulation of the immune system. Nevertheless, the activation of these processes in AGA is illustrated by the over-expression of genes encoding chemokines, immunoglobulins, mast cell markers and MHC class II molecules. Our results also bring evidence of the crucial role of the Wnt/β-catenin signaling pathway in hair physiology, indicating that its inhibition in AGA subjects can be triggered by an increased expression of SFRP2 as well as in some extent by a decreased *CTNNB1* and *LEF1* expression. A reduced β -catenin activity should indeed impair HF integrity and regeneration. Moreover, the alteration of β -catenin stabilization might be linked to the decreased expression of POMC at both RNA and protein levels through the loss of the inhibitory effect of α -MSH on GSK3 β . Inhibition of β-catenin activity can be also achieved by an increase production of DHT in the AGA group as a consequence of the higher expression of SRD5A2. In addition, we showed that other components might contribute to this inhibition. Indeed, a reduced expression of *BMP2* and *ITGB6* should impact negatively the TGF- β transcriptional activity and TGF- β activation of the Wnt/ β -catenin signaling, respectively. Although the upstream mechanisms

by which modulation of these genes is achieved in AGA remain to be determined, the increased *SFRP2* expression might result in part from an altered metabolism of vitamin D3. The under-expression of *CYP27B1* leading to a reduced production of calcitriol, known to inhibit *DKK1* and *SFRP2* expression, might contribute to reduce the β -catenin activity.

Altogether, these data bring new evidences that distinct altered mechanisms converging to inhibit Wnt/β -catenin signaling account for AGA in young male subjects. They also evidence B and T cell involvement suggesting an underlying autoimmune-related mechanism that remains to be further highlighted.

CONFLICT OF INTEREST

"The authors state no conflict of interest."

ACKNOWLEDGEMENT

This study was financed by IEB-Lucas Meyer cosmetics and Laboratoire BIO-EC for the project entitled ALOCA (Consortium Cosmetic Valley - Ile de France). High throughput RTqPCR analysis was carried out on the qPCR-HD-Genomic Paris Centre platform and was supported by grants from Région Ile-de-France and Fondation Pierre-Gilles de Gennes. Stefan Tomiuk from Miltenyi Biotec was in charge of the bioinformatical analysis of whole genome microarray data.

REFERENCES

- Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951; 53:708 28.
- 2 Heilmann-Heimbach S, Hochfeld LM, Paus R, *et al.* Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Exp Dermatol. 2016; 25:251-7.
- 3 Bergfeld WF. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995; 98:95S-98S.
- 4 Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010; 11:1295-304.
- 5 Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol 2001; 116:452-5.
- 6 Hillmer AM, Hanneken S, Ritzmann S, *et al.* Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet 2005; 77: 140-8.
- 7 Kretzschmar K, Cottle DL, Schweiger PJ, *et al.* The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. J Invest Dermatol. 2015; 135:2753-63.
- 8 Adhikari K, Fontanil T, Cal S, *et al.* A genome-wide association scan in admixed Latin Americans identifies loci influencing facial and scalp hair features. Nat Commun. 2016; 7:10815.
- 9 Hillmer AM, Flaquer A, Hanneken S, *et al*. Genome-wide scan and fine mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet 2008; 82: 737-43.
- 10 Heilmann-Heimbach S, Hochfeld LM, Paus R, Nöthen MM. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Exp Dermatol. 2016;25:251-7.
- 11 Garza LA, Yang CC, Zhao T, *et al.* Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. J Clin Invest 2011; 121:613–22.
- 12 Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alphareductase genes. J Invest Dermatol 1998; 110:849-53.
- 13 Nyholt DR, Gillespie NA, Heath AC, *et al.* Genetic basis of male pattern baldness. J Invest Dermatol 2003; 121: 1561-4.
- 14 Landel V, Baranger K, Virard L, et al. Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease. Mol. Neurodegeneration. 2014; 9:33.
- 15 Bégué E, Jean-Louis F, Bagot M, *et al.* Inducible expression and pathophysiological functions of T-plastin in cutaneous T-cell lymphoma. Blood. 2012; 120:143-54.
- 16 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
- 17 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
- 18 Ito T, Hashizume H, Shimauchi T, *et al.* CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci. 2013; 69:140-7.
- 19 Ito T, Tokura Y. The role of cytokines and chemokines in the T-cell-mediated autoimmune process in alopecia areata. Exp Dermatol. 2014; 23:787-91.

- 20 Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203-10.
- 21 Salmi M, Jalkanen S. Ectoenzymes in leukocyte migration and their therapeutic potential. Semin Immunopathol. 2014; 36:163-76.
- 22 Khoury EL, Price VH, Greenspan JS. HLA-DR expression by hair follicle keratinocytes in alopecia areata: evidence that it is secondary to the lymphoid infiltration. J Invest Dermatol. 1988; 90:193-200.
- 23 Won CH, Kwon OS, Kim YK, *et al.* Dermal fibrosis in male pattern hair loss: a suggestive implication of mast cells. Arch Dermatol Res. 2008; 300:147-52.
- 24 Martins VL, Caley M, O'Toole EA. Matrix metalloproteinases and epidermal wound repair. Cell Tissue Res. 2013; 351:255-68.
- 25 Maeda K, Nishiyama C, Ogawa H, *et al.* GATA2 and Sp1 positively regulate the c-kit promoter in mast cells. J Immunol. 2010; 185:4252-60.
- 26 Garza LA, Liu Y, Yang Z, *et al.* ProstaglandinD2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med 2012; 4 126ra34.
- 27 Nelson AM, Loy DE, Lawson JA, *et al.* Prostaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44. J Invest Dermatol. 2013; 133:881-9.
- 28 Alonso L, Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev. 2003; 17:1189-200.
- 29 Jansson L, Kim GS, Cheng AG. Making sense of Wnt signaling-linking hair cell regeneration to development. Front Cell Neurosci. 2015; 9:66.
- 30 Leirós GJ, Attorresi AI, Balañá ME. Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/β-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. Br J Dermatol. 2012; 166:1035-42.
- 31 Heilmann S, Kiefer AK, Fricker N, *et al.* Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013; 133:1489-96.
- 32 Kim JK, Kim E, Baek IC, *et al.* Overexpression of Hr links excessive induction of Wnt signaling to Marie Unna hereditary hypotrichosis. Hum Mol Genet. 2010; 19:445-53.
- 33 Niida A, Hiroko T, Kasai M, *et al.* DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene. 2004; 23:8520-6.
- 34 Kwack MH, Kim MK, Kim JC, *et al.* Dickkopf 1 promotes regression of hair follicles. J Invest Dermatol. 2012; 132:1554-60.
- 35 Rutberg SE, Kolpak ML, Gourley JA, *et al.* Differences in expression of specific biomarkers distinguish human beard from scalp dermal papilla cells. J Invest Dermatol. 2006; 126:2583-95.
- 36 Kim BK, Yoon SK. Expression of sfrp2 is increased in catagen of hair follicles and inhibits keratinocyte proliferation. Ann Dermatol. 2014; 26:79-87.
- 37 Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol. 2009; 174:715-21.
- 38 Wang T, Chai R, Kim GS, *et al.* Lgr5+ cells regenerate hair cells via proliferation and direct transdifferentiation in damaged neonatal mouse utricle. Nat Commun. 2015; 6:6613.
- 39 O'Shaughnessy RF, Christiano AM, Jahoda CA. The role of BMP signalling in the control of ID3 expression in the hair follicle. Exp Dermatol. 2004; 13:621-9.
- 40 Sekiya T, Oda T, Matsuura K, *et al.* Transcriptional regulation of the TGF-beta pseudoreceptor BAMBI by TGF-beta signaling. Biochem Biophys Res Commun. 2004; 320:680-4.
- 41 Lin Z, Gao C, Ning Y, *et al.* The pseudoreceptor BMP and activin membrane-bound inhibitor positively modulates Wnt/beta-catenin signaling. J Biol Chem. 2008; 283:33053-8.

- 42 Behrens J, von Kries JP, Kühl M, *et al.* Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996; 382(6592):638-42.
- 43 Huber O, Korn R, McLaughlin J, *et al.* Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev. 1996; 59:3-10.
- 44 Kratochwil K, Dull M, Farinas I, *et al.* Lef1 expression is activated by BMP-4 and regulates inductive tissue interactions in tooth and hair development. Genes Dev. 1996; 10:1382-94.
- 45 Ahmed MI, Alam M, Emelianov V, *et al.* MicroRNA-214 controls skin and hair follicle development by modulating the activity of the Wnt pathway. J Cell Biol. 2014; 207:549-67.
- 46 Huelsken J, Vogel R, Erdmann B, *et al.* beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell. 2001; 105:533-45.
- 47 Ito N, Ito T, Kromminga A, *et al.* Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J. 2005; 19:1332-4.
- 48 Bellei B, Pitisci A, Catricalà C, *et al.* Wnt/β-catenin signaling is stimulated by α-melanocytestimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res. 2011; 24:309-25.
- 49 Hahm S, Mizuno TM, Wu TJ, *et al.* Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance. Beuron 1999; 23:537-48.
- 50 Enshell-Seijffers D, Lindon C, Wu E, *et al.* Beta-catenin activity in the dermal papilla of the hair follicle regulates pigment-type switching. Proc Natl Acad Sci U S A. 2010; 107:21564-9.
- 51 Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997; 109:296-300.
- 52 Kitagawa T, Matsuda K, Inui S, *et al.* Keratinocyte growth inhibition through the modification of Wnt signaling by androgen in balding dermal papilla cells. J Clin Endocrinol Metab. 2009; 94:1288-94.
- 53 Akhmetshina A, Palumbo K, Dees C, *et al.* Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun. 2012; 3:735.
- 54 Xie Y, McElwee KJ, Owen GR, *et al.* Integrin β6-deficient mice show enhanced keratinocyte proliferation and retarded hair follicle regression after depilation. J Invest Dermatol. 2012; 132:547-55.
- 55 Foitzik K, Paus R, Doetschman T, *et al.* The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev Biol. 1999; 212:278-89.
- 56 Inoue K, Aoi N, Yamauchi Y, *et al.* TGF-beta is specifically expressed in human dermal papilla cells and modulates hair folliculogenesis. J Cell Mol Med. 2009;13:4643-56.
- 57 Morgan MR, Jazayeri M, Ramsay AG, *et al.* Psoriasin (S100A7) associates with integrin β6 subunit and is required for ανβ6-dependent carcinoma cell invasion. Oncogene. 2011; 30: 1422-35.
- 58 Kizawa K, Takahara H, Unno M, et al. S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles. Biochimie. 2011; 93:2038-47.
- 59 Midorikawa T, Chikazawa T, Yoshino T, *et al.* Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA macroarray analysis. J Dermatol Sci. 2004; 36:25-32.
- 60 Park GT, Morasso MI. Bone morphogenetic protein-2 (BMP-2) transactivates Dlx3 through Smad1 and Smad4: alternative mode for Dlx3 induction in mouse keratinocytes. Nucleic Acids Res. 2002; 30:515-22.

- 61 Owens P, Bazzi H, Engelking E, *et al.* Smad4-dependent desmoglein-4 expression contributes to hair follicle integrity. Dev Biol. 2008; 322:156-66.
- 62 Mardaryev AN, Ahmed MI, Vlahov NV, *et al*. Micro-RNA-31 controls hair cycle-associated changes in gene expression programs of the skin and hair follicle. FASEB J. 2010; 24:3869-81.
- 63 Hwang J, Mehrani T, Millar SE, *et al.* Dlx3 is a crucial regulator of hair follicle differentiation and cycling. Development. 2008; 135:3149-59.
- 64 Jave-Suarez LF, Winter H, Langbein L, *et al.* HOXC13 is involved in the regulation of human hair keratin gene expression. J Biol Chem. 2002; 277:3718-26.
- 65 Kulessa H, Turk G, Hogan BL. Inhibition of Bmp signaling affects growth and differentiation in the anagen hair follicle. EMBO J. 2000; 19:6664-74.
- 66 Fujikawa H, Fujimoto A, Farooq M, *et al.* Characterization of the human hair keratin-associated protein 2 (KRTAP2) gene family. J Invest Dermatol. 2012; 132:1806-13.
- 67 Fujimoto S, Takase T, Kadono N, *et al.* Krtap11-1, a hair keratin-associated protein, as a possible crucial element for the physical properties of hair shafts. J Dermatol Sci. 2014;74:39-47.
- 68 Kasper M, Regl G, Frischauf AM, *et al.* GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer. 2006; 42:437-45.
- 69 Ryan JW, Anderson PH, Morris HA. Pleiotropic Activities of Vitamin D Receptors Adequate Activation for Multiple Health Outcomes. Clin Biochem Rev. 2015; 36:53-61.
- 70 Sakai Y, Kishimoto J, Demay MB. Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest. 2001; 107:961-6.
- 71 Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011; 347:90-6.
- 72 Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem. 2007; 101:80-8.
- 73 Baltalarli B, Bir F, Demirkan N, *et al.* The preventive effect of vitamin D3 on radiation-induced hair toxicity in a rat model. Life Sci. 2006; 78:1646-51.
- 74 Puchacz E, Stumpf WE, Stachowiak EK, *et al.* Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res Mol Brain Res. 1996; 36:193-6.
- 75 Marles LK, Peters EM, Tobin DJ, *et al.* Tyrosine hydroxylase isoenzyme I is present in human melanosomes: a possible novel function in pigmentation. Exp Dermatol. 2003; 12:61-70.
- 76 Enshell-Seijffers D, Lindon C, Morgan BA. The serine protease Corin is a novel modifier of the Agouti pathway. Development. 2008; 135:217-25.
- 77 Rendl M, Polak L, Fuchs E. BMP signaling in dermal papilla cells is required for their hair follicle-inductive properties. Genes Dev. 2008; 22:543-57.
- 78 Bazzi H, Getz A, Mahoney MG, et al. Desmoglein 4 is expressed in highly differentiated keratinocytes and trichocytes in human epidermis and hair follicle. Differentiation. 2006; 74:129-40.
- 79 Qiu W, Lei M, Tang H, et al. Hoxc13 is a crucial regulator of murine hair cycle. Cell Tissue Res. 2016; 364:149-58.
- 80 Hammond NL, Jahoda CA. Id2, Id3, and Id4 proteins show dynamic changes in expression during vibrissae follicle development. Dev Dyn. 2008; 237:1653-61.
- 81 Rendl M, Lewis L, Fuchs E. Molecular dissection of mesenchymal-epithelial interactions in the hair follicle. PLoS Biol. 2005; 3:e331.
- 82 Bernot KM, Coulombe PA, McGowan KM. Keratin 16 expression defines a subset of epithelial cells during skin morphogenesis and the hair cycle. J Invest Dermatol. 2002; 119:1137-49.

- 83 Ohyama M, Kobayashi T, Sasaki T, et al. Restoration of the intrinsic properties of human dermal papilla in vitro. J Cell Sci. 2012; 125:4114-25.
- 84 Jaks V, Barker N, Kasper M, et al. Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet. 2008; 40:1291-9.
- 85 Ma L, Liu J, Wu T, Plikus M, et al. 'Cyclic alopecia' in Msx2 mutants: defects in hair cycling and hair shaft differentiation. Development. 2003; 130:379-89.
- 86 Kono M, Nagata H, Umemura S, et al. In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin. FASEB J. 2001; 15:2297-9.
- 87 Böhm M, Eickelmann M, Li Z, et al. Detection of functionally active melanocortin receptors and evidence for an immunoregulatory activity of alpha-melanocyte-stimulating hormone in human dermal papilla cells. Endocrinology. 2005; 146:4635-46.
- 88 Caglayan AO, Dundar M, Tanriverdi F, et al. Idiopathic hirsutism: local and peripheral expression of aromatase (CYP19A) and 5α-reductase genes (SRD5A1 and SRD5A2). Fertil Steril. 2011; 96:479-82.
- 89 Soma T, Tsuji Y, Hibino T. Involvement of transforming growth factor-beta2 in catagen induction during the human hair cycle. J Invest Dermatol. 2002; 118:993-7.

TABLES

| Expression trend | Gene numbers p≤0.05; FC≥1.5x | Adjusted gene numbers p≤0.05; FC≥1.5x |
|------------------|---------------------------------|--|
| A > C | 325 | 149 |
| A < C | 390 | 184 |

Table 1 - Number of candidate reporters returned by the DGAs (FC: fold-change).

Table 2 - Synopsis of up- or down-regulated gene family. Most prominent findings of the Functional Annotation (FA) analysis, highlighted in beige and of the Annotation Enrichment (AEA) analysis, shown with blue background.

| A > C | A < C |
|--|----------------------------------|
| Innate Immunity | Cytoskeleton |
| Extracellular matrix (some collagens) | Cell adhesion |
| Receptor signaling | Keratin-associated proteins |
| Response to toxins | subset of keratins |
| B-cell Immunity | connexins/cell communication |
| Cell differentiation | TGF-beta signaling pathway |
| Cell proliferation | endopeptidase inhibitor activity |
| Inflammation | EGF-like protein domain |
| T-cell Immunity | growth factor activity |
| Cell migration | Platelet Activation |
| Angiogenesis | spermatogenesis |
| Development | |
| Cell adhesion | |
| Repressed by IL7 Pathway (only 4 genes) | |
| Induced by IL1 Pathway (only 5 genes) | |
| immunoglobulins (antibody chains) | |
| pos. regulation of leukocyte/T-cell activation | |
| some MHC II molecules with various associated categories | |
| some cytokines/chemokines associated with various signaling pathways | |
| cellular calcium ion homeostasis | |
| IFNg response | |
| metalloprotease activity | |

| Immune and | Average expression values | | P values | Mean of fc | Nbr. of AGA patients for: | | | |
|--------------------|------------------------------|-------|----------|-----------------|---------------------------|--------|-------|--|
| inflammatory genes | AGA | CTRL. | | in all patients | fc \ge 1.5 and \le 2 | fc > 2 | Total | |
| CCL13 | 683 | 351 | ** | 3.1 ± 1.0 | 1 | 12 | 13/14 | |
| CXCL10 | 24 | 10 | * | 4.2 ± 2.5 | 0 | 12 | 12/14 | |
| CXCL12 | 15025 | 9940 | *** | 1.5 ± 0.2 | 8 | 1 | 9/14 | |
| CCL8 | 21 | 12 | ** | 2.4 ± 0.9 | 3 | 8 | 11/14 | |
| CCL18 | 1842 | 595 | * | 20.0 ± 14.7 | 0 | 13 | 13/14 | |
| CCL26 | 50 | 27 | * | 3.0 ± 1.5 | 4 | 9 | 13/14 | |
| TNFRSF17 | 17 | 4 | * | 8.7±5.4 | 1 | 13 | 14/14 | |
| CD38 | 33 | 11 | * | 9.7 ± 4.7 | 0 | 14 | 14/14 | |
| IRF4 | 43 | 26 | *** | 2.1 ± 0.5 | 4 | 7 | 11/14 | |
| HLA-DPB1 | 3666 | 2557 | ** | 1.8 ± 0.4 | 5 | 6 | 11/14 | |
| HLA-DQA1 | 1216 | 310 | ** | 11.4 ± 8.0 | 1 | 12 | 13/14 | |
| HLA-DRB3 | 683 | 351 | *** | 2.0 ± 0.5 | 7 | 5 | 12/14 | |
| HLA-DRB4 | 3979 | 2086 | ** | 2.5 ± 0.8 | 1 | 10 | 11/14 | |
| MS4A2 | 527 | 352 | *** | 1.8 ± 0.2 | 7 | 4 | 11/14 | |

Table 3A – Differential gene expression between AGA patients and controls.

| ECM genes | Average e valu | • | P values | Mean of fc | Nbr. of AGA pation | ents for: | | |
|------------|-------------------|-----------|----------|------------------|----------------------------|-----------|-------|--|
| | AGA | CTRL. | | in all patients | fc \geq 1.5 and \leq 2 | fc > 2 | Total | |
| COL1A1 | 24812 | 11937 | ** | 2.9 ± 0.9 | 2 | 11 | 13/14 | |
| COL1A2 | 26931 | 15195 | ** | 2.1 ± 0.5 | 3 | 8 | 11/14 | |
| MMP12 | 46 | 13 | * | 12.3±8.9 | 0 13 | | 13/14 | |
| MC markers | Average e valu | xpression | P values | Mean of fc | Nbr. of AGA patients for: | | | |
| | AGA | CTRL. | | in all patients | fc \ge 1.5 and \le 2 | fc > 2 | Total | |
| TPSAB1 | 2627 | 1630 | *** | 2.1 ± 0.4 | 3 | 9 | 12/14 | |
| TPSD1 | 2154 | 1308 | *** | 2.3 ± 0.8 | 4 | 7 | 11/14 | |
| CMA1 | 784 | 511 | ** | 2.2 ± 0.6 | 2.2±0.6 4 7 | | 11/14 | |
| CTSG | 43 | 26 | *** | 2.3 ± 0.4 | 1 | 12 | 13/14 | |
| PTGDS | 9301 | 5162 | ** | 2.7 ± 0.7 | 3 | 11 | 14/14 | |

The average of gene expression values (A.U.) were obtained for selected genes from bioinformatical analysis, with p values established between AGA and control (CTRL) subjects. The mean of fold change (fc) in all subjects and standard deviations were deduced from the mean of the ratios (value of AGA subjects *versus* controls) for each AGA subject. The number of patients eliciting a modulated expression according to the selected threshold is indicated.

p values: *< 0.05; ** <0.01; *** < 0.001.

| Genes | Average expression values | | P values | Mean of fc | Nbr. of AGA pation | ents for: | | |
|--------|------------------------------|-------|----------|------------------|---------------------------|-----------|-------|--|
| | AGA | CTRL. | | in all patients | fc \leq 0.7 and >0.5 | fc ≤ 0.5 | Total | |
| LGR5 | 70 | 125 | *** | 0.5 ± 0.2 | 2 | 9 | 11/14 | |
| ID3 | 1176 | 1445 | * | 0.7 ± 0.1 | 7 | 0 | 7/14 | |
| MSX2 | 31 | 48 | 0.09 | 0.4 ± 0.2 | 0 | 10 | 10/14 | |
| ALAD | 544 | 697 | * | 0.7 ± 0.1 | 7 | 2 | 9/14 | |
| BAMBI | 2114 | 3695 | * | 0.4 ± 0.2 | 2 | 10 | 12/14 | |
| LEF1 | 863 | 1221 | 0.10 | 0.6 ± 0.2 | 4 | 6 | 10/14 | |
| CTNNB1 | 504 | 683 | ** | 0.8 ± 0.1 | 6 | 0 | 6/14 | |
| РОМС | 368 | 628 | *** | 0.5 ± 0.2 | 3 | 9 | 12/14 | |
| VGF | 124 | 335 | * | 0.3 ± 0.2 | 1 | 12 | 13/14 | |
| Genes | Average e valu | | P values | Mean of fc | Nbr. of AGA patients for: | | | |
| | AGA | CTRL. | · functo | in all patients | fc \ge 1.5 and \le 2 | fc > 2 | Total | |
| SFRP2 | 828 | 407 | ** | 3.3±1.1 | 2 | 12 | 14/14 | |
| ASIP | 334 | 202 | ** | 2.3 ± 0.6 | 5 | 8 | 13/14 | |
| CORIN | 422 | 229 | *** | 2.3 ± 0.3 | 3 | 11 | 14/14 | |
| SRD5A2 | 96 | 59 | ** | 2.2 ± 0.7 | 2 | 8 | 10/14 | |

Table $3B - Wnt/\beta$ -catenin signaling related genes

The average of gene expression values (A.U.) and the means of fold change (fc) were calculated as in Table 3A.

| Genes | Average expression values | | P values | Mean of fc | Nbr. of AGA patients for: | | | |
|--------|------------------------------|-------|----------|-----------------|---------------------------|----------|-------|--|
| | AGA | CTRL. | | in all patients | fc \leq 0.7 and >0.5 | fc ≤ 0.5 | Total | |
| TGFB2 | 23 | 39 | *** | 0.5 ± 0.1 | 6 | 6 | 12/14 | |
| ITGB6 | 24 | 43 | *** | 0.5 ± 0.1 | 2 | 10 | 12/14 | |
| BMP2 | 31 | 48 | * | 0.4 ± 0.1 | 4 | 9 | 13/14 | |
| DSG4 | 180 | 346 | * | 0.6 ± 0.3 | 0 | 11 | 11/14 | |
| DLX3 | 401 | 653 | * | 0.5 ± 0.2 | 2 | 9 | 11/14 | |
| KRT16 | 27980 | 46982 | *** | 0.6±0.2 | 6 | 6 | 12/14 | |
| НОХС13 | 569 | 1066 | ** | 0.4 ± 0.2 | 3 | 9 | 12/14 | |

Table 3C - TGB β /BMP-signaling related genes

The average of gene expression values (A.U.) and the means of fold change (fc) were calculated as in Table 3A.

Table 3D – Vitamin D3 – related genes

| Genes | Average expression values | | P values | Mean of fc in all patients | Nbr. of AGA patie | | |
|---------|------------------------------|-------|----------|-------------------------------|-------------------|----------|-------|
| | AGA | CTRL. | | in an patients | fc ≤ 0.7 and >0.5 | fc ≤ 0.5 | Total |
| СҮР27В1 | 107 | 176 | * | 0.5 ± 0.2 | 3 | 9 | 12/14 |
| ТН | 63 | 98 | * | 0.6+/-0.1 | 4 | 8 | 12/14 |

The average of gene expression values (A.U.) and the means of fold change (fc) were calculated as in Table 3A.

Table 4 – Score of staining intensity of POMC and ASIP/PARD3 according to their distribution along the hair follicle.

| Score of staining intensity | | | | | | | | | |
|-----------------------------|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |

| Volunteer | POMC Infundibulum + Upper root sheath | POMC Bulge | POMC Lower root sheath | POMC Bulb | ASIP/PARD3 Infundibulum + Upper root sheath | ASIP/PARD3 Bulge | ASIP/PARD3 Lower root sheath | ASIP/PARD3 Bulb |
|--------------|--|------------|------------------------------|-----------|--|---------------------|------------------------------------|--------------------|
| Control 1 | 8 | 7 | 5 | 4 | 6 | 5 | 6 | 4 |
| Control 2 | 8 | 5 | 5 | 2 | 5 | 6 | 5 | 5 |
| Control 3 | 7 | 4 | 6 | | 5 | 4 | 5 | 6 |
| Control 4 | 7 | 7 | 3 | 2 | 4 | 3 | 3 | 5 |
| Control 5 | 6 | 2 | 2 | 2 | 3 | 4 | 4 | |
| Control 6 | 7 | 5 | 4 | 4 | 2 | 4 | 4 | 7 |
| Control 7 | 7 | 5 | 4 | | 3 | 5 | 2 | |
| Control 8 | 7 | 5 | 4 | 3 | 2 | | 2 | 7 |
| Control 9 | 6 | 5 | 2 | 3 | 2 | 1 | 3 | 7 |
| Control 10 | 7 | 5 | 2 | 3 | 2 | 5 | 3 | 5 |
| Control 11 | 8 | 7 | 5 | 6 | 2 | 4 | 4 | 2 |
| Control 12 | 5 | 2 | 2 | | 3 | 4 | 3 | 2 |
| Control 13 | 7 | 4 | 2 | | 3 | 4 | 4 | |
| Control 14 | 7 | 4 | 2 | 2 | 3 | 4 | 3 | 3 |
| | | | | | | | | |
| AGA 1 | 4 | 2 | 2 | 3 | 3 | 3 | 4 | |
| AGA 2 | 6 | 2 | 2 | 1 | 2 | 3 | 4 | 3 |
| AGA 3 | 4 | 1 | 1 | 1 | 3 | 1 | 2 | |
| AGA 4 | 4 | 1 | 2 | 4 | 2 | 3 | 4 | 2 |
| AGA 5 | 4 | 1 | 1 | 2 | 2 | 2 | 3 | 1 |
| AGA 6 | 4 | 1 | 3 | 0 | 2 | 2 | 3 | 2 |
| AGA 7 | 5 | 2 | 2 | 1 | 2 | 3 | 2 | 1 |
| AGA 8 | 3 | 1 | 1 | | 3 | 1 | 2 | 3 |
| AGA 9 | 4 | | 1 | | 3 | 3 | 4 | 1 |
| AGA 10 | 3 | 2 | 2 | 1 | 4 | 4 | 4 | 1 |
| AGA 11 | 6 | 2 | 2 | 1 | 4 | 5 | 5 | 3 |
| AGA 12 | 2 | 2 | 1 | 1 | 4 | 2 | 3 | 2 |
| AGA 13 | 2 | 1 | 1 | | 1 | 2 | 4 | 5 |
| AGA 14 | 2 | 1 | | | 2 | 2 | 3 | 2 |
| | POMC Infundibulum + Upper root sheath | POMC Bulge | POMC Lower root sheath | POMC Bulb | ASIP/PARD3 Infundibulum + Upper root sheath | ASIP/PARD3 Bulge | ASIP/PARD3 Lower root sheath | ASIP/PARD3 Bulb |
| Ratio AGA/CT | 0,6 | 0,3 | 0,5 | 0,5 | 0,8 | 0,6 | 0,9 | 0,4 |
| p value | 0,000001 | 0,000001 | 0,0002 | 0,005 | 0,10 | 0,001 | 0,21 | 0,0005 |

LEGENDS TO FIGURES

Figure 1. Photographs of two representative AGA subjects (A) and two representative control volunteers (C).

Arrows indicate the site where the scalp biopsies were carried out.

Figure 2. Transcriptomic analysis of scalp biopsies from subjects with AGA (A) and controls (C).

Histogram of differentially expressed genes between alopecia and control volunteers depicts a quite similar number of significantly upregulated and downregulated genes. Blue bar charts and orange bar charts represent Up-regulated and Down-regulated genes in group A *versus* group C, respectively. Legend shows 3 groups of fold changes (fc): fc > 2.5, fc > 2 and < 2.5 and fc >1.5 and <2 for up-regulated genes and fc < -2.5, fc > -2.5 and < -2 and fc < -1.5 and >-2.

Figure 3 – Hierarchically clustered heat maps (Euclidean distance, complete linkage) of reporters with higher expression in the alopecia group (A) relative to the healthy controls (C) (two-dimensional clustering)

Figure 4 - Gene expression analysis of some key factors by qPCR

Selection of differentially expressed genes in volunteers with AGA compared to control ones was obtained after DGA and functional analysis, completed by PredictSearch one. Results are presented as fold changes in mean gene expression (alopecia/control samples), with n=14 samples for each group. $\dagger p < 0.1$; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.001.

Figure 5 – Immunohistochemistry staining

POMC (4A) and ASIP/PARD3 (4B) immunostaining in the main areas of the hair follicle as depicted in one representative control group volunteer and one representative AGA group volunteer. POMC and ASIP/PARD3 are visualized with AlexaFluor 488 (green) and nuclear staining with propidium iodide (red). Colors and numbers as indicated by the "score of staining intensity" (table 4) represent the intensity of the immunolabeling found for POMC and ASIP according to their distribution along the hair follicle, ranging from 1 (the lowest) to 8 (the highest) staining intensity. Magnification x63.

Figure 6 – Schematic representation of signaling pathways in AGA.

Schematic representation of functional networks. Functional correlations between the modulated genes was designed with the help of the text-mining software PredictSearch (see materials and methods). Modulated genes in AGA are indicated in blue when overexpressed or in red when underexpressed in AGA *versus* volunteers.

*, **, ***, **** indicate in which compartment(s) of the hair follicle (hair matrix, dermal papilla, outer root sheath or inner root sheath, respectively), the gene expression was reported to be detected, with respective references as following: ASIP ⁷⁶, BAMBI ⁷⁷, BMP2 ⁷⁷, CORIN ⁷⁶, CTNNB1 ^{46, 50}, DLX3 ⁶³, DSG4 ⁷⁸, HOXC13 ⁷⁹, ID3 ⁸⁰, ITGB6 ⁸¹, KRT16 ⁸², LEF1 ⁸³, LGR5 ⁸⁴, MSX2 ⁸⁵, POMC ^{86, 87}, SFRP2 ³⁵, SRD5A2 ⁸⁸, TGFB2 ^{89, 56}, TH ⁸².



